Defining the region(s) of deletion at 6q16–q22 in human prostate cancer

✍ Scribed by Eija-Riitta Hyytinen; Rega Saadut; Ceshi Chen; Lindsay Paull; Pasi A. Koivisto; Robert L. Vessella; Henry F. Frierson Jr.; Jin-Tang Dong

• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: English
• Weight: 200 KB
• Volume: 34
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.10065

✦ Synopsis

Abstract

Deletion of the long arm of chromosome 6 (6q) frequently occurs in many neoplasms, including carcinomas of the prostate and breast and melanoma, suggesting the location of a tumor‐suppressor gene or genes at 6q. At present, however, the region of deletion has not been well defined, and the target gene of deletion remains to be identified. In this study, we analyzed 44 primary prostate cancers with 16 polymorphic markers for loss of heterozygosity (LOH) by using PCR‐based techniques. We also examined 23 cell lines/xenografts of prostate cancer with 38 markers for LOH by the method of homozygosity mapping of deletion. LOH at 6q16–q22 was detected in 21 of 44 (48%) primary tumors and in 12 of 23 (52%) cell lines/xenografts. Two regions of LOH were defined. One was 7.5 cM at 6q16–q21 between markers D6S1716 and D6S1580, and the other was 4.3 cM at 6q22 between D6S261 and D6S1702. Whereas no correlation was found between LOH at 6q16–q22 and patient age at diagnosis or Gleason score, tumors at higher stage appear to have more frequent LOH. These findings suggest that deletion of 6q16–q22 is a frequent event in prostate cancer, and that the deletion originates from two distinct regions. These results should be useful in identifying the target gene(s) of deletion at 6q. © 2002 Wiley‐Liss, Inc.